{
    "clinical_study": {
        "@rank": "66962", 
        "acronym": "HEALTH-DB ACS", 
        "arm_group": {
            "arm_group_label": "1"
        }, 
        "brief_summary": {
            "textblock": "Thi is an observational, non interventional, cohort analysis by using administrative\n      databases (drugs treatment, laboratory and diagnostic tests, specialist visits and\n      hospitalizations) of Sicilia region to evaluate treatment patterns of patients after Acute\n      Coronary Syndrome (ACS) event."
        }, 
        "brief_title": "Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Coronary Syndrome", 
            "Acute Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "HEALTH-DB ACS"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects discharged alive from hospitalization for ACS\n\n        Exclusion Criteria:\n\n          -  All patients that don't have a continuative presence as beneficiaries of the region\n             between January 1st, 2007 and December 31st 2011 will be excluded from analysis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients discharged alive from an hospitalization for Acute Myocardial Infarction\n        (AMI) between January, 1st 2008 and December, 31st 2010 (inclusion period) will be\n        included into analysis. The discharge date will be defined as \"inclusion date\"."
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678339", 
            "org_study_id": "NIS-CIT-XXX-2012/1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ACS", 
            "AMI"
        ], 
        "lastchanged_date": "October 2, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Palermo", 
                    "country": "Italy"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca CLINICAL RESEARCH DIRECTOR", 
                "last_name": "Flore La Tour", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "AstraZeneca Italy - VP MEDICAL", 
                "last_name": "Raffaele Sabia", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Department of Pharmaceutical Health - SICILIAN REGION", 
                "last_name": "Rosalia Traiana, Doctor of Pharmacology", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_outcome": [
            {
                "measure": "The diagnostic path for each patient included in the analysis will be described by using all prescription for laboratory test (eg. total cholesterol, LDL cholesterol) and/or diagnostics tests (eg. electrocardiogram) during the observation period.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "The drugs treatment path will be described by using all prescriptions of antihypertensive drugs, lipid-lowering drugs and antiplatelet drugs during the observation period.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Adherence to treatment will be calculated in the manner suggested by the literature and used in previous publications.  Different methods of assessment will, however, used in order to study the variability of results. The analysis will be conducted over", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "The chronological analysis of the requirements will allow the identification of potential therapeutic combinations or substitutions.", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}